In intestinal L-cells - concentrated in the distal ileum and colon - PC1/3 processes proglucagon into GLP-1 , GLP-2, glicentin, and oxyntomodulin
Based on a retrospective study of self-reported data of pounds lost for active versus passive users who were offered the Noom program when being prescribed an early stage GLP-1
Rosenstock J, Hsia S, Ruiz LN et al (2025) Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes
In addition to dietary and pharmaceutical influences, new research confirms that GLP-1 secretion is impacted by sex as well as many personal health factors, including glucose tolerance and overall metabolic health, body weight, microbiome composition, and even eating behaviour itself (Huber et al., 2024)
Tolerability profile comparative data All three molecules share a typical GI adverse event profile, decreasing with progressive titration
The initiation dose is sub-therapeutic